Will the FDA accept an NDA/BLA filing from RVMD for daraxonrasib by December 31, 2026?

This market is conditional on RASolute 302 success (~40% probability). Even with positive data, NDA preparation typically takes 3-6 months. If readout occurs in H1 2026 (say May-June), the earliest filing would be August-November 2026. Breakthrough Therapy Designation allows rolling review, which could compress the timeline. But FDA acceptance of the filing requires complete data package review. The CNPV accelerates review after filing, not filing itself. Probability is roughly P(302 success) × P(filing by Dec 31 | success) = 0.40 × 0.65 = 0.26, adjusted slightly up for BTD rolling review advantage.

Even assuming RASolute 302 reads out in Q2 2026 as expected, the path to FDA filing acceptance by year-end requires: (1) positive data, (2) rapid NDA preparation, (3) rolling submission under BTD, (4) FDA acceptance within 60 days. The nested trial design adds complexity to the data package. Manufacturing CMC data must also be filed. Each step has execution risk. Companies with BTD typically file 2-4 months faster than standard pathway, but even with that advantage, the timeline from mid-2026 data to year-end filing acceptance is tight.

RVMD has been preparing for this moment — commercial team build, regulatory infrastructure, and pre-NDA meetings with FDA likely already conducted. Companies with BTD and pre-NDA alignment can submit rolling NDAs starting before the final data cut. If RVMD began rolling submission modules (CMC, nonclinical) before the Phase III readout, the clinical module could be added rapidly after positive results. This scenario pushes probability slightly above the conditional calculation. But the overall probability remains constrained by the ~40% chance of positive data.

Two gates: Phase III success and regulatory filing speed. ~40% chance of success × ~55% chance of filing acceptance within 6 months of positive data (BTD helps but December 31 is a hard cutoff). That gives ~22%. The rolling review advantage is real but FDA still needs time to process the accept/refuse decision.

The BTD rolling review is a material advantage. RVMD likely has pre-submission modules prepared given the commercial buildout already underway. If data reads out in May 2026, a rolling NDA could be substantially complete by September, with FDA acceptance by November-December. This is aggressive but achievable. The probability is primarily gated by the Phase III outcome. If we assume RVMD has planned for rapid filing, P(filing acceptance by Dec | positive data) could be 60-70%, making the combined probability 0.40 × 0.65 = 0.26.

The 8+ registrational trials suggest RVMD's regulatory team may be stretched across multiple programs. Even with BTD, preparing a complete NDA package for daraxonrasib while managing enrollment and conduct of 6+ other trials is operationally demanding. The probability of filing acceptance by December 31 is constrained by both the trial outcome and operational bandwidth.

Conditional probability: ~40% trial success × ~55% rapid filing = ~22%. BTD helps but the combined probability of two sequential events is low.

Even with the strongest possible preparation, FDA filing acceptance by December 2026 requires both positive data and rapid execution. The combined probability is in the low-to-mid 20s. The CNPV and BTDs provide real advantages but cannot overcome the fundamental binary risk of the Phase III trial.

Two independent events both need to occur: positive Phase III data AND filing acceptance. Each individually is uncertain. Combined probability roughly 0.40 × 0.58 = 0.23.